vs
China SXT Pharmaceuticals, Inc.（SXTC）与武田制药（TAK）财务数据对比。点击上方公司名可切换其他公司
武田制药的季度营收约是China SXT Pharmaceuticals, Inc.的5.1倍（$4.3M vs $829.5K）。武田制药净利率更高（3.4% vs -96.8%，领先100.1%）
中国SXT药业是一家聚焦中国本土市场的制药企业，主要从事中药类处方药、非处方药物及营养保健品的研发、生产与销售，服务覆盖临床医疗机构与大众健康消费两大板块。
武田制药是总部位于日本的跨国制药企业，为亚洲第三大制药公司，全球营收排名位列前二十。集团全球员工超4.95万人，核心业务聚焦肿瘤、罕见病、神经科学、消化疾病及血浆衍生疗法等领域。
SXTC vs TAK — 直观对比
营收规模更大
TAK
是对方的5.1倍
$829.5K
净利率更高
TAK
高出100.1%
-96.8%
损益表 — Q2 2026 vs Q1 2025
| 指标 | | |
|---|---|---|
| 营收 | $829.5K | $4.3M |
| 净利润 | $-802.6K | $144.2K |
| 毛利率 | 16.2% | 66.5% |
| 营业利润率 | -76.9% | 5.0% |
| 净利率 | -96.8% | 3.4% |
| 营收同比 | 0.0% | — |
| 净利润同比 | 0.0% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SXTCTAK
| Q3 25 | $829.5K | — | ||
| Q2 25 | — | $4.3M | ||
| Q3 24 | $829.5K | — | ||
| Q1 24 | — | $4.0M | ||
| Q3 23 | $939.6K | — | ||
| Q3 22 | $1.2M | — | ||
| Q3 21 | $1.0M | — |
净利润SXTCTAK
| Q3 25 | $-802.6K | — | ||
| Q2 25 | — | $144.2K | ||
| Q3 24 | $-802.6K | — | ||
| Q1 24 | — | $317.0K | ||
| Q3 23 | $-9.7M | — | ||
| Q3 22 | $-1.5M | — | ||
| Q3 21 | $-3.1M | — |
毛利率SXTCTAK
| Q3 25 | 16.2% | — | ||
| Q2 25 | — | 66.5% | ||
| Q3 24 | 16.2% | — | ||
| Q1 24 | — | 69.1% | ||
| Q3 23 | 30.7% | — | ||
| Q3 22 | 7.4% | — | ||
| Q3 21 | 31.5% | — |
营业利润率SXTCTAK
| Q3 25 | -76.9% | — | ||
| Q2 25 | — | 5.0% | ||
| Q3 24 | -76.9% | — | ||
| Q1 24 | — | 12.2% | ||
| Q3 23 | -995.0% | — | ||
| Q3 22 | -95.2% | — | ||
| Q3 21 | -281.4% | — |
净利率SXTCTAK
| Q3 25 | -96.8% | — | ||
| Q2 25 | — | 3.4% | ||
| Q3 24 | -96.8% | — | ||
| Q1 24 | — | 7.9% | ||
| Q3 23 | -1032.0% | — | ||
| Q3 22 | -123.7% | — | ||
| Q3 21 | -300.9% | — |
每股收益（稀释后）SXTCTAK
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $-0.25 | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $-19.34 | — | ||
| Q3 22 | $-14.61 | — | ||
| Q3 21 | $-3.98 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.1M | $2.5B |
| 总债务越低越好 | $105.0K | — |
| 股东权益账面价值 | $15.4M | $45.1B |
| 总资产 | $21.7M | $92.6B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资SXTCTAK
| Q3 25 | $18.1M | — | ||
| Q2 25 | — | $2.5B | ||
| Q3 24 | $18.5M | — | ||
| Q1 24 | — | $3.0B | ||
| Q3 23 | $11.5M | — | ||
| Q3 22 | $3.0M | — | ||
| Q3 21 | $31.3K | — |
总债务SXTCTAK
| Q3 25 | $105.0K | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $952.3K | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $106.6K | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
股东权益SXTCTAK
| Q3 25 | $15.4M | — | ||
| Q2 25 | — | $45.1B | ||
| Q3 24 | $15.0M | — | ||
| Q1 24 | — | $47.3B | ||
| Q3 23 | $5.1M | — | ||
| Q3 22 | $14.5M | — | ||
| Q3 21 | $13.8M | — |
总资产SXTCTAK
| Q3 25 | $21.7M | — | ||
| Q2 25 | — | $92.6B | ||
| Q3 24 | $31.0M | — | ||
| Q1 24 | — | $98.2B | ||
| Q3 23 | $14.6M | — | ||
| Q3 22 | $22.2M | — | ||
| Q3 21 | $22.7M | — |
负债/权益比SXTCTAK
| Q3 25 | 0.01× | — | ||
| Q2 25 | — | — | ||
| Q3 24 | 0.06× | — | ||
| Q1 24 | — | — | ||
| Q3 23 | 0.02× | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | — |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -216.2% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流SXTCTAK
| Q3 25 | $-1.4M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $-1.4M | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $-579.6K | — | ||
| Q3 22 | $-549.1K | — | ||
| Q3 21 | $-312.3K | — |
自由现金流SXTCTAK
| Q3 25 | $-1.8M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
自由现金流率SXTCTAK
| Q3 25 | -216.2% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
资本支出强度SXTCTAK
| Q3 25 | 4.9% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
